UCB SA - BNP Paribas Fortis

marketing and supply agreement dated May 1999 which was terminated by Novartis in 2007. The term
of the agreement is until 31 December 2016.
On 24 August 2009 Novartis and Schwarz Pharma Deutschland GmbH entered into two further copromotion
agreements, one for Novartis’ product Dafiro®, and one for Novartis’ products Jalra® and
Icandra®. Both agreements run until 31 August 2019.
Osmotica Pharmaceutical Corp.
UCB has an exclusive license to sell the venlafaxine extended-release tablet product from Osmotica
Pharmaceutical Corp. in the U.S. The term of the agreement extends until 14 July 2013.
Otsuka Pharmaceutical Company Limited
In November 2002, Otsuka Pharmaceuticals and Schwarz Pharma entered into a development, license
and supply agreement for Neupro® (rotigotine) in Japan. Under this agreement, Otsuka
Pharmaceuticals develops Neupro® (rotigotine) for the Japanese market and has been granted exclusive
licence rights under Neupro® (rotigotine) patents and know-how for Japan.
In June 2008, Otsuka Pharmaceuticals and UCB entered into co-promotion and co-development
agreements in relation to Cimzia® in Japan and Korea, and Keppra® in Japan. The term of each of
these agreements is, in relation to Cimzia®, for a period of 11 years after the date of launch of the
licensed product, and in relation to Keppra® for a period of ten years after the launch of the licensed
product. A co-promotion agreement between Otsuka Pharmaceuticals and UCB in relation to PletaaL®
in Japan was also entered into in June 2008.
Pfizer Inc.
In April 2006, Pfizer Inc, Schwarz Pharma and Schwarz Pharma Limited/Ireland entered into an
agreement under which Pfizer was granted a worldwide exclusive license under patents and know-how
related to fesoterodine. The product Toviaz® for fesoterodine has already been launched by Pfizer in
the US and Europe. The initial term of the agreement runs until the occurrence of Significant Generic
Competition (as defined in the agreement), on a country-by-country and licensed product-by licensed
product basis.
Sanofi-Aventis US LLC
In September 2006, UCB Inc. and Sanofi-Aventis US LLC. entered into an agreement to co-promote
Xyzal® (levocetirizine) in the United States. The agreement extends until 31 December 2013.
(b) Research and Development Agreements
Amgen Inc.
An exclusive collaboration and license agreement entered in May 2002 by Celltech R&D Limited, an
entity which was acquired by the UCB Group in connection with its acquisition of Celltech in 2004, and
Amgen Inc. to develop, market and sell antibody products targeting the sclerostin protein, including
CDP7851. The agreement expires if the parties cease to develop or commercialise the licensed product.
Harris FRC
In December 1999, Harris FRC and Schwarz Pharma entered into a development agreement on the
development by Schwarz of lacosamide; in particular in the indications of epilepsy and neuropathic
A11250830/2.25/23 Oct 2009 84